Morganella morganii is a gram negative, rod-shaped bacteria that is naturally occurring in the human gut. It is a motile, aerobic, facultative anaerobic, and a member of the Enterobactiaceae. This bacteria is usually grouped within the genus Proteus as these two genera do share many common characteristics. However, there are some very different traits in these two genera. One of the biggest differences is that swarming in Morganella does not occur, unlike that of Proteus. As stated above, this bacteria is a common inhabitant in the human gut, specifically the colon, but it is also present in water and soil. Morganella is the common culprit for many different diseases including, urinary tract infections, summer diarrhea and nosocomial infectionss (O'Hara et al., 2000). Morganella is an opportunistic invader and will take advantage of a compromised immune system. Accordingly, Morganella infection is prevalent in hospital settings after a surgery, or throughout the healing of a serious wound (Kim et al., 2007).
Antibiogram and Genotypic Analysis using 16S rDNA after Biofield Treatment on Morganella morganii
Morganella morganii (M. morganii) is one of the important nosocomial pathogen associated with the urinary tract infections and bacteremia. The aim of this study was to evaluate the effect of Mr. Trivedi’s biofield energy treatment on M. morganii in the lyophilized as well as revived state for antimicrobial susceptibility pattern, biochemical characteristics, biotype number and genotype. M. morganii cells were procured from MicroBioLogics Inc., USA in sealed packs bearing the American Type Culture Collection (ATCC 25829) number and stored according to the recommended storage protocols until needed for experiments. M. morganii strain was divided into two groups, Group (Gr.) I: control and Gr. II: treated. Gr. II was further subdivided into two groups, Gr. IIA and Gr. IIB. Gr. IIA was analyzed on day 10, while Gr. IIB was stored and analyzed on day 142 (Study I). After retreatment on day 142, the sample (Study II) was divided into three separate tubes. First, second and third tube was further analyzed on day 5, 10 and 15 respectively. All experimental parameters were studied using the automated MicroScan Walk-Away® system. The 16S rDNA sequencing of lyophilized treated sample was carried out to correlate the phylogenetic relationship of M. morganii with other bacterial species. Antimicrobial susceptibility results showed 32.14% alterations, while minimum inhibitory concentration results showed 18.75% alterations of the tested antimicrobials. Biochemical study also showed altered positive reactions in nitrofurantoin and indole with respect to control. Biotype study showed alteration in Gr. IIB, study II, on day 15 (4005 1446) as compared to the control (4004 1446). 16S rDNA sequencing analysis showed similar results with the identified microbe as M. morganii (GenBank accession number: AB210972) having 80% identity of the gene sequencing data. Total 1507 base nucleotide of 16S rDNA gene sequences were analyzed by multiple alignments, while nearest homolog genus-species of M. morganii was found as Providencia rettgeri (accession number: AM040492). These results suggested that biofield treatment has a significant impact on M. morganii in lyophilized as well as revived state.
Morganella is a gram negative bacteria that are shaped as straight rods. These rods are usually between 0.6 and 0.7 um in diameter and 1.0 to 1.8 um in length. Morganella is both motile and non-motile depending on the environmental temperature at which it is present. Most bacteria of this genera form flagella at temperatures below 30 degrees Celsius, allowing for rapid movement. In environments above 30 degrees Celsius, Morganella usually will not form the flagella. Unlike some of its close ancestors this bacteria does not swarm (O'Hara et al., 2000).
M. morganii is present in the human gut, specifically in the colon. It does have the ability to enter the urethra, which is where it can cause urinary tract infections but this is mostly seen in women. Morganella is also present in soil and water and has been seen in other mammals, such as dogs and cats. Additionally, Morganella has been known to cause the death of chickens. When the host’s immune system is suppressed, M. morganii will rapidly invade the host and also cause specific IgA responses and as well as cause an the increase in the volume of Peyer’s patches. M. morganii is isolated much like the other Enterobacteriaceae. It is cultured from fecal specimen and is often enriched using tetrathioate and selenite that are added to nutrient broth. It is differentiable from Proteus in that its is urease and indole positive, does not swarm, and is negative for most of the biochemical reactions that are seen with the Proteus species (O'Hara et al., 2000).
Morganella is naturally occurring in the flora of the gut and is not antagonistic until a traumatic event of the host. Due to its highly mobile state, Morganella is able to rapidly colonize the gut. Coupled with enlargement of the Peyer’s patches in the gut and specific IgA responses, it is able to change the environment of the host very quickly. This bacterium is also known to invade the urinary tract. Since the bacteria is urease positive, it can hydrolyze urea in the urine to form ammonia - leading to a rise in the pH of the urine. This can have many adverse effects including the formation of stones causing renal damage, and it can also lead to a urinary tract infection (Manos & Belas, 2006).
Diseases and Parasites
As an opportunistic secondary invader that takes advantage of a compromised immune system, Morganella can be a causative agent of many nosocomial infections, including urinary tract infections and wound and blood infections. As a result, there are many unique Morganella cases and it is difficult to predict when a Morganella infection will occur (O'Hara et al., 2000). This bacteria has many virulence factors. M. morganii contains ureases which have a high affinity for urea. It is able to survive in acidic conditions and its ureases are activated within the gut by the presence of low pH levels. Morganella is also able to synthesize extracellular hemolysin much like E. coli. The hemolysin in M. morganii is very different then those produced by some other bacteria in that it is extracellular which could be accounted for by the presence of the secretory gene hlyD in M. morganii (Manos & Belas, 2006). This bacteria also has the ability to hydrolyze and modify antibiotics through the presence of adhesins and other enzymes.
Life History and Behavior
M. morganii is motile via the use of a flagella. In some cases, it reacts to changes in the pH of the gut as well as to changes in the state of the immune system. Since it is an opportunistic pathogen, it takes advantage of a compromised immune system and that it why it is mostly seen in hospitals after a serious injury or surgery.
Evolution and Systematics
The first isolation of this bacteria was done by a man named Castellani in 1905, and he named it Bacterium columbensea. In 1906 when Morgan came across this bacteria while studying summer infantaile diarrhea, he was unaware that it was indeed the same bacteria that was found by Castellani. Morgan described this as a non-lactose fermenting bacteria - different from the other Bacillus type bacteriia. He named this Morgan's Bacillus and it was later named, in 1919, Bacillus morganii by Winslow. Years later, Rauss performed further evaluation of the bacteria and realized it was very similar to the Proteus group and although there were marked differences, he renamed the bacteria Proteus morganii. Finally in 1943, Fulton made the connection that the bacteria Proteus morganii was in fact the same bacteria discovered by Castellani in 1905 and he proposed a new genus name of Morganella. The species would be called M. morganii and Castellani's species would be called M. columbensis. M. morganii was unable to ferment lactose or sucrose but was able to produce indole. In 1962, Ewing found the M. columbensis was actually E. coli, which left M. morganii as the only species in the genus. This led Ewing to disregard the genus and relate moganii to the Proteus genus. Finally in 1976, morganii was put in its rightful place in the genus of Morganella. The differentiation between the two genera was finally made by Brenner using DNA-DNA hybridization, which showed less then 20% homology between P. morganii and Proteus. The differences were further backed by the ability for trehalose fermentation (O'Hara et al., 2000). Morganella is also distinguishable from the genus Proteus by the lysine iron agar test and by the ability of the genus Proteus to differentiate in to swarmer cells when colonizing a new habitat (Manos & Belas, 2006).
Physiology and Cell Biology
Morganella has been classified as both aerobic and facultatively anaerobic.It is able to ferment sugar and is glucose positive. It is also catalase and phenylalanine positive. Morganella exhibits both a respiratory and fermentative type of metabolism (O'Hara et al., 2000). M. morganii is naturally resistant to drugs like penicillin, ampicillin, oxacillin, and erythromycin (Manos & Belas, 2006).
Molecular Biology and Genetics
Morganella is a motile bacterium via the use of a flagella. This bacteria can be non-motile if the temperature drops below 30 degrees Celsius where the flagella is incapable of forming (O'Hara et al., 2000). The Morganella morganii genome is 3.83 Mb and has a GC content of 51.1 %. (NCBI). Under certain conditions, Morganella has been shown to produce histamine, which can lead to toxic conditions if the temperature is correct. At a temperature of 25 degrees Celsius, the Morganella bacterium will produce 5,253 ppm and this will lead to toxic conditions in the host (Kim et al., 2000). Further research is being done on additional Morganella species, especially the proposed subspecies M. morgnaii sibonii (O'Hara et al., 2000).
Relevance to Humans and Ecosystems
Currently there is no information about the applications for this bacterium other then maintaining certain levels in your gut to keep everything in equilibrium. This is done naturally in a healthy body.
Morganella morganii is a species of Gram-negative bacteria. It has a commensal relationship within the intestinal tracts of humans, mammals, and reptiles as normal flora. Although M. morganii has a wide distribution, it is considered an uncommon cause of community-acquired infection and it is most often encountered in postoperative and other nosocomial infections such as urinary tract infections.
Historical identification and systematics
M. morganii was first described by a British bacteriologist H. de R. Morgan in 1906 as Morgan's bacillus. Morgan isolated the bacterium from stools of infants who were noted to have had "summer diarrhea". Later in 1919, Winslow et al. named Morgan's bacillus, Bacillus morganii. In 1936, though, Rauss renamed B. morganii as Proteus morganii. Fulton, in 1943, showed that B. columbensis and P. morganii were the same and defined the genus Morganella, due to the DNA-DNA hybridization. M. morganii has two subspecies - M. m. morganii and M. m. columbensis. However in 1962, a review article by Ewing reported that M. columbensis had been reidentified as Escherichia coli, therefore removing that organism from the genus., Morganella.
Morganella morganii is facultatively anaerobic and oxidase-negative. Its colonies appear off-white and opaque in color, when grown on agar plates. M. morganii cells are straight rods, about 0.6-0.7 µm in diameter and 1.0-1.7 µm in length. This organism moves by way of peritrichous flagella, but some strains do not form flagella at 30°C.
M. morganii can produce the enzyme catalase, so is able to convert hydrogen peroxide to water and oxygen. This is a common enzyme found in most living organisms. In addition, it is indole test-positive representing this organism can split tryptophan to indole, pyruvate, and ammonia. Methyl red tests positive in M.morganii, an indicator dye that turns red in acidic solutions. Although a rare human pathogen, M. morganii has been reported as a cause of urinary tract infections, nosocomial surgical wound infections, peritonitis, central nervous system infection, endophthalmitis, pneumonia, chorioamnionitis, neonatal sepsis, pyomyositis, necrotizing fasciitis, and arthritis. Numerous cases of nosocomial infection have been described, usually as postsurgical wound infections or urinary tract infections. Patients in whom bacteremia develops are typically immunocompromised, diabetic, or elderly, or have at least one serious underlying disease.
Role of bacteria
M. morganii is a member of the tribe Proteeae (normal fecal flora that often causes infection in patients whose normal flora have been disturbed by antibiotic therapy) of the family Enterobacteriaceae, with two species: M. morganii and M. sibonii. M. morganii has been regarded as a harmless opportunistic pathogen, but some strains carry "antibiotic-resistant plasmids" and have been associated with nosocomial outbreaks of infections. Several reports indicate M. morganii causes sepsis, ecthyma, endophthalmitis, and chorioamnionitis, and more commonly urinary tract infections, soft tissue infections, septic arthritis, meningitis, and bacteremia, often with fatal consequences.
In a rare case published in 2003, a patient presented with bilateral necrosis of both upper and lower eyelids. Upon microbial analysis, the areas were shown to have heavy growth of M. morganii.
Treatment and antibiotic resistance
Treatment of M. morganii infections may include:
- Third-generation and fourth-generation cephalosporins
A study conducted at the University Hospital at Heraklion, Crete, Greece showed a 92% success rate in the use of these antibiotics.
However, some M. morganii strains are resistant to penicillin, ampicillin/sulbactam, oxacillin, first-generation and second-generation cephalosporins, macrolides, lincosamides, fosfomycin, colistin, and polymyxin B. The emergence of highly resistant strains of M. morganii have been associated with use of third-generation cephalosporins.
Polymicrobial infections are most abundantly caused by this microbe which additionally damages the skin, soft tissues, and urogenital tract; these can be cured through use of the aforementioned antibiotics.
- eMedicine. Morganella infections
- UniProt. Morganella morganii (Proteus morganii)
- "Morganella infections". Medscape. Retrieved 12.5.2012. Check date values in:
- Pulaski, M.D., E.J.; G. W. Deitz, M.D. (September 14, 1940). JAMA 115 (11): 922–923. doi:10.1001/jama.1940.72810370001008.
- Chen, Yu-Tin; Hwei-Ling Peng2, Wei-Chung Shia3, Fang-Rong Hsu4,5, Chuian-Fu Ken6, Yu-Ming Tsao7, Chang-Hua Chen8, Chun-Eng Liu8, Ming-Feng Hsieh1, Huang-Chi Chen9, Chuan-Yi Tang1,10*, Tien-Hsiung Ku7 (3–5 Oct 2012). "Whole-genome sequencing and identification of Morganella morganii KT pathogenicity-related genes". BMC Genomics 13: 1471–2164. doi:10.1186/1471-2164-13-s7-s4.
- O'Hara, Caroline Mohr; Frances W. Brenner,2 and J. Michael Miller (13 October 2000). "Classification, identification, and clinical significance of Proteus, Providencia, and Morganella.". Clinical Microbiology Reviews. 4 13 (4): 534–546. doi:10.1128/cmr.13.4.534-546.2000. PMC 88947. PMID 11023955.
- Herrara, Jose. "Morganella morganii". Truman State University Biology. Truman State University. Retrieved 12.06.2012. Check date values in:
- "Morganella morganii". University of Windsor. Retrieved 12.6.12. Check date values in:
- Cunha MD, Burke. "Proteeae Infections". Merck Manual. Retrieved 12.08.12. Check date values in:
- Senior, W; S. Voros (1990). Journal of Medical Microbiology 33 (4): 259–264 http://jmm.sgmjournals.org/content/33/4/259.full.pdf
|url=missing title (help).
- Singla, Nidhi; Neelam Kaistha; Neelam Gulati; Jagdish Chander (Jul–Sep 2010). "Morganella morganii could be an important intensive care unit pathogen". Indian Journal of Critical Care Medicine 14 (3): 154–155. doi:10.4103/0972-5229.74176. PMC 3021833. PMID 21253351.
- Shenoy MD; AU Shenoy; AM Rajay; ZH al Mahrooqui (2003). "Necrotic Periorbital Ulceration due to Morganella morganii". Asian Journal of Ophthalmology. 1 5.
- Falagas, M.E.; P.K. Kavvadia, E. Mantadakis, D.P. Kofteridis, I.A. Bliziotis, E. Saloustros, S. Maraki, G. Samonis (2006). "Morganella morganii infections in General Tertiary Hospital". Clinical and Epidemiology Study 6: 315–321. doi:10.1007/s15010-006-6682-3. Retrieved 12.08.12. Check date values in:
EOL content is automatically assembled from many different content providers. As a result, from time to time you may find pages on EOL that are confusing.
To request an improvement, please leave a comment on the page. Thank you!